Introduction: Intravenous iloprost is currently recommended in the treatment of Raynaud's phenomenon (RP) refractory to oral therapy and of digital ulcers (DUs) related to systemic sclerosis (SSc). In real-life practice there is a huge heterogeneity about the Iloprost regimens used. Methods: A survey was carried out on SSc patients that interrupted Iloprost infusion to compare acral vascular symptoms just before Iloprost withdrawal and just after the missed infusion. Severity, and frequency of RP, new DUs onset or aggravation of those pre-existing were reported. Last available capillaroscopic images were also evaluated. Results: The analysis includes 50 patients. After iloprost withdrawal, 11 patients reported a RP worsening because of enhanced intensity (p = 0.007). Only 8 patients of them also complained of an increased frequency (p = 0.07). None of the patients experienced digital ulcers for the first-time during quarantine. Among the 27 patients with a history of digital ulcers, 9 reported worsening and 7 recurrence of DUs. Overall, 17 patients (34.0 %) complained of a worsening of SSc vascular acral manifestations, namely RP or DUs. Reduced capillary density was associated with RP worsening, in particular, each unit increase of capillary density corresponds to an average 44 % decrease in the odds of RP worsening (OR 0.56, CI 95 % 0.36-0.97, p = 0.037). As for RP worsening, the aggravation of DU was associated with a lower capillary density. Conclusions: Low capillary density can predict a worsening of both RP and DUs in controlled quarantine con-ditions within a month after iloprost discontinuation in SSc patients.

De Lorenzis, E., Natalello, G., Verardi, L., Cerasuolo, P. G., Gigante, L., D'Agostino, M. A., Bosello, S. L., Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic, <<MICROVASCULAR RESEARCH>>, 2022; 144 (144): 104404-N/A. [doi:10.1016/j.mvr.2022.104404] [https://hdl.handle.net/10807/221893]

Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic

Verardi, Lucrezia;Cerasuolo, Pier Giacomo;D'Agostino, Maria Antonietta;Bosello, Silvia Laura
2022

Abstract

Introduction: Intravenous iloprost is currently recommended in the treatment of Raynaud's phenomenon (RP) refractory to oral therapy and of digital ulcers (DUs) related to systemic sclerosis (SSc). In real-life practice there is a huge heterogeneity about the Iloprost regimens used. Methods: A survey was carried out on SSc patients that interrupted Iloprost infusion to compare acral vascular symptoms just before Iloprost withdrawal and just after the missed infusion. Severity, and frequency of RP, new DUs onset or aggravation of those pre-existing were reported. Last available capillaroscopic images were also evaluated. Results: The analysis includes 50 patients. After iloprost withdrawal, 11 patients reported a RP worsening because of enhanced intensity (p = 0.007). Only 8 patients of them also complained of an increased frequency (p = 0.07). None of the patients experienced digital ulcers for the first-time during quarantine. Among the 27 patients with a history of digital ulcers, 9 reported worsening and 7 recurrence of DUs. Overall, 17 patients (34.0 %) complained of a worsening of SSc vascular acral manifestations, namely RP or DUs. Reduced capillary density was associated with RP worsening, in particular, each unit increase of capillary density corresponds to an average 44 % decrease in the odds of RP worsening (OR 0.56, CI 95 % 0.36-0.97, p = 0.037). As for RP worsening, the aggravation of DU was associated with a lower capillary density. Conclusions: Low capillary density can predict a worsening of both RP and DUs in controlled quarantine con-ditions within a month after iloprost discontinuation in SSc patients.
Inglese
De Lorenzis, E., Natalello, G., Verardi, L., Cerasuolo, P. G., Gigante, L., D'Agostino, M. A., Bosello, S. L., Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic, <<MICROVASCULAR RESEARCH>>, 2022; 144 (144): 104404-N/A. [doi:10.1016/j.mvr.2022.104404] [https://hdl.handle.net/10807/221893]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/221893
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact